Nascent Biotech, Inc. (OTCMKTS:NBIO – Get Free Report)’s share price crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.03 and traded as low as $0.01. Nascent Biotech shares last traded at $0.01, with a volume of 24,200 shares.
Nascent Biotech Trading Down 16.7 %
The stock has a 50-day moving average of $0.03 and a 200 day moving average of $0.05.
Nascent Biotech Company Profile
Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.
Further Reading
- Five stocks we like better than Nascent Biotech
- What Investors Need to Know to Beat the Market
- 3 Stocks With Robust Growth Outlooks Insiders Are Buying
- How to Effectively Use the MarketBeat Ratings Screener
- Buffett’s Billion-Dollar Bet: Will Constellation Brands Pay Off?
- Investing In Preferred Stock vs. Common Stock
- Dutch Bros: Percolating Higher on Hypergrowth, More Upside to Go
Receive News & Ratings for Nascent Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nascent Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
